<DOC>
	<DOCNO>NCT01999114</DOCNO>
	<brief_summary>The purpose study evaluate ECG effect 10 , 40 , 80 mcg/hr buprenorphine deliver BTDS alone , BTDS dose naltrexone , relative placebo healthy male female subject .</brief_summary>
	<brief_title>The Effect Buprenorphine Delivered Buprenorphine Transdermal System ( BTDS ) Doses 80 Micrograms/Hour ( Mcg/hr ) Naltrexone Electrocardiogram ( ECG ) Intervals Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Provide write informed consent . Males female age 18 55 , inclusive . Body weight range 50 100 kilogram ( kg ) ( 110 220 lb ) body mass index ( BMI ) range 18 30 ( kg/m2 ) , inclusive . Healthy free significant abnormal finding determine medical history , physical examination , clinical laboratory value , vital sign , rest 12lead ECG . Females childbearing potential must use adequate reliable method contraception ( ie , barrier additional spermicidal foam jelly , intrauterine device , hormonal contraception ) . Females postmenopausal must postmenopausal ≥ 1 year elevate serum follicle stimulate hormone ( FSH ) . Willing eat food supply study . Willing refrain strenuous exercise entire study . Subjects begin new exercise program participate unusually strenuous physical exertion . All 8 anatomical transdermal system ( TDS ) application site ( upper back , upper chest , upper outer arm , lateral thorax ) must acceptable study use . Females pregnant ( positive beta human chorionic gonadotropin test ) lactating . Current recent ( within 5 year ) history drug alcohol abuse . History current condition might interfere drug absorption ( transdermal gastrointestinal ) , distribution , metabolism excretion . Use opioidcontaining medication past 30 day precede initial dose study . Known allergy buprenorphine , excipient BTDS , opioids , psychotropic hypnotic drug , and/or moxifloxacin member quinolone class drug . Any history frequent nausea emesis regardless etiology . Any history seizure head trauma sequela . Participation clinical drug study 30 day precede initial dose study . Any significant illness 30 day precede initial dose study . Use medication include thyroid hormonal therapy ( hormonal contraception hormonal replacement therapy form estrogen without progestin allow ) , vitamin , herbal and/or mineral supplement 7 day precede initial dose . Any personal family history prolong QT interval disorder cardiac rhythm . Abnormal cardiac condition include hypertension . Abnormal cardiac condition denote follow : QTcF interval &gt; 450 millisecond ( msec ) PR interval &gt; 240 msec QRS &gt; 110 msec Evidence second thirddegree atrioventricular ( AV ) block Pathological Qwaves ( define Qwave &gt; 40 msec depth &gt; 0.5 mV ) Evidence ventricular preexcitation , complete leave bundle branch block , right bundle branch block ( RBBB ) , incomplete RBBB With rest heart rate outside range 45 85 beat per minute ( bpm ) Abnormalities physical examination , vital sign , ECG , clinical laboratory value , unless abnormality judge clinically insignificant investigator . Oxygen saturation ( SpO2 ) ≤ 94 % measure pulse oximetry . Refusal abstain caffeine xanthine contain beverage entirely confinement . Refusal abstain consumption alcoholic beverages 48 hour prior initial study drug administration time study . History smoking use nicotine product within 45 day study drug administration positive urine cotinine test Blood blood product donate within 30 day prior study drug administration anytime study . Positive result urine drug screen alcohol screen . Positive result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( antiHCV ) . Positive naloxone challenge test . Presence Gilbert 's Syndrome , know hepatobiliary abnormality . The investigator believe subject unsuitable reason ( ) specifically state exclusion criterion . Subjects allergies contraindication transdermal system patch adhesive . Clinically significant history allergic reaction wound dressing elastoplast . Subjects dermatological disorder relevant patch application site precludes proper placement and/or rotation patch . Taking antihistamine within 72 hour prior dose systemic topical corticosteroid within 3 week prior dose . Subjects allow hair remove propose patch application site may prevent proper placement patch . Subjects proper assessment possible application site reaction would confound local skin condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Opioid</keyword>
	<keyword>Transdermal</keyword>
	<keyword>ECG</keyword>
</DOC>